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Abstract 
Background: The emergence of artemisinin-resistant Plasmodium falciparum strains poses a serious challenge to the 
control of malaria. This necessitates the development of new anti-malarial drugs. Previous studies have shown that 
the natural beta-carboline alkaloid harmine is a promising anti-malarial agent targeting the P. falciparum heat-shock 
protein 90 (PfHsp90). The aim of this study was to test the anti-malarial activity of harmine analogues.
Methods: Forty-two harmine analogues were synthesized and the binding of these analogues to P. falciparum heat 
shock protein 90 was investigated. The in vitro anti-malarial activity of two of the analogues, 17A and 21A, was evalu-
ated using a 72-h growth inhibition assay. The in vivo anti-malarial activity was tested in Plasmodium berghei infec-
tion of BALB/c mice. The potential of 21A for a combination treatment with artemisinin was evaluated using in vivo 
combination study with dihydro-artemisinin in BALB/c mice. Cytotoxicity of the harmine analogues was tested in vitro 
using HepG2 and HeLa cell lines.
Results: 17A and 21A bound to PfHsp90 with average IC50 values of 12.2 ± 2.3 and 23.1 ± 8.8 µM, respectively. They 
also inhibited the P. falciparum W2 strain with average IC50 values of 4.2 ± 1.3 and 5.7 ± 1.7 µM, respectively. In vivo, 
three daily injections of P. berghei-infected BALB/c mice with 100 mg/kg of either 17A or 21A showed significant 
reduction in parasitaemia with a 51.5 and 56.1% reduction, respectively. Mice treated with 17A and 21A showed 
a median survival time of 11 and 14 days, respectively, while the vehicle control mice survived a median of only 
8.5 days. A dose-ranging experiment with 21A showed that the compound has a dose-dependent anti-malarial effect. 
Furthermore, treatment of infected mice with a combination of 21A and dihydroartemisinin (DHA) showed a dramatic 
reduction in parasitaemia compared to treatment with DHA alone.
Conclusion: A novel and non-toxic harmine analogue has been synthesized which binds to PfHsp90 protein, inhibits 
P. falciparum in vitro at micromolar concentration, reduces parasitaemia and prolongs survival of P. berghei-infected 
mice with an additive anti-malarial effect when combined with DHA.
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Background
Malaria is one of the leading causes of morbidity and 
mortality from infectious diseases. A recent report by 
World Health Organization (WHO) estimated that 3.2 
billion people are at risk of contracting the disease. In 
2015 alone, there were an estimated 214 million cases of 
malaria worldwide with 438,000 deaths. Ninety per cent 
of the deaths occurred in WHO African Region where 
children are the main victims [1].
Multidimensional intervention in malaria control 
over the last decade has significantly reduced the inci-
dence and mortality caused by malaria worldwide. 
These include the provision of insecticide-treated bed 
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nets, indoor residual spraying, rapid diagnostic tests, 
and a supply of effective artemisinin-based combina-
tion therapy (ACT). As a result, many countries have 
initiated malaria elimination programmes. However, the 
emergence of Plasmodium falciparum strains that are 
resistant to artemisinin in Southeast Asian countries is 
posing a huge challenge to future malaria control and 
elimination efforts. The possibility of dissemination of 
the resistant strains to Africa is projected to have poten-
tially catastrophic outcomes [1]. This calls for the urgent 
search for new and effective anti-malarial drugs.
Currently, ACT is the most widely used treatment for 
uncomplicated malaria. Since artemisinin is a fast-acting 
drug with a short half-life, it should be combined with 
another drug with longer half-life in order to effectively 
clear the parasite and prevent the emergence of drug-
resistant strains. Several partner drugs have been used as 
a component of ACT. Unfortunately, treatment failures in 
the partner drugs have emerged, threatening to curb the 
positive achievements gained to date in the fight against 
malaria and exposing artemisinin [2–4]. This necessitates 
the development of new partner drugs to use in ACT in 
places where resistance to artemisinin has not developed.
Heat shock proteins (Hsps) are the major chaperone 
proteins found in all life forms, ranging from prokaryotes 
to higher organisms, such as plants and mammals. Hsps 
are both constitutive and stress-inducible [5, 6]. Environ-
mental factors, such as an abrupt change in temperature, 
upregulates the expression of Hsps [7, 8].
The life cycle of parasites such as Plasmodium, Leish-
mania and Trypanosoma involves poikilothermic insect 
vectors and homoeothermic mammalian hosts. These 
parasites are exposed to a sudden change in temperature 
of up to 10 °C during the transition from the insect-stage 
to mammalian-stage of the parasites, and have evolution-
arily developed molecular chaperones to withstand the 
drastic change in temperature [9, 10]: for example, about 
2% of the genes of P. falciparum code for proteins that 
serve as molecular chaperones [9]. Su and Wellems [11] 
showed that transcription of P. falciparum heat shock 
protein 90 (PfHsp90) increases up to three- and four-fold 
as a result of in vitro cultivation of the parasite at 39 and 
41 °C, respectively.
Depending on their molecular size, Hsps are classi-
fied as small heat shock proteins (sHsps), Hsp40, Hsp60, 
Hsp70, Hsp90, and Hsp110. Hsp90 is one of the most 
abundant cytosolic proteins of a eukaryotic cell. The 
N-terminal domain of Hsp90 has an ATP binding pocket 
responsible for its ATPase activity [12, 13]. Hsps play a 
crucial role in the normal metabolic activities of cells. 
By facilitating the proper folding of proteins, Hsps are 
involved in intracellular protein trafficking, gene expres-
sion, cell cycle, as well as cell differentiation [5, 9, 14].
The crucial role of Hsp90 in chaperoning several 
important cellular functions and the structural differ-
ences in the ATP-binding domain of human and parasite 
Hsp90 make it a potentially viable drug target against 
several parasitic infectious diseases [15, 16]. Molecu-
lar characterization of the PfHsp90 protein from clini-
cal isolates of P. falciparum collected from patients in 
diverse geographical regions has shown that the ATP-
binding domain of PfHsp90 is highly conserved among 
the isolates [17] thus reducing the likelihood of resistance 
emerging. Hsp90 is an essential protein in eukaryotic sys-
tems and not compatible with viability if knocked out. 
That is, mutations in the ATP binding domain of PfHsp90 
make the protein inactive, negatively affecting important 
biological functions and incur the parasite too much fit-
ness cost [18–20]. Interestingly, it has been shown that 
PfHsp90 may be associated with a P. falciparum chlo-
roquine resistance transporter (PfCRT) protein from a 
chloroquine-resistant parasite strain. Immunoprecipi-
tation experiments showed that PfHsp90 complex co-
immunoprecipitated with PfCRT from P. falciparum W2 
strain. Moreover, the use of a PfHsp90 inhibitor, PU-H71, 
resulted in loss of PfCRT protein [21]. It is postulated 
that targeting PfHsp90 in chloroquine-resistant P. falci-
parum strain could reverse the resistance and render the 
parasite chloroquine sensitive again. This effect may not 
be restricted to a single drug class given the broad range 
of chaperone activity that Hsp90 regulates.
The discovery of the natural compound, geldanamycin 
opened a new avenue in the development of drugs tar-
geting Hsp90. Geldanamycin has displayed a strong anti-
cancer and anti-malarial effect in vitro. However, a strong 
hepatotoxic signal precludes its clinical use. As a result, 
different derivatives of geldanamycin have been devel-
oped that have an acceptable level of hepatotoxicity [22]. 
In  vitro and in  vivo experiments have shown that the 
geldanamycin-derivatives, 17AAG and 17-PEG-Alkyn-
GA, are promising anti-malarial compounds targeting 
PfHsp90 [23, 24].
In addition to geldanamycin and its derivatives, other 
small molecules such as purine analogues have been 
found to effectively inhibit Hsp90 in  vitro and in  vivo. 
One such molecule is PU-H71. This molecule has been 
tested as an anti-cancer drug [25]. Recently, it has been 
demonstrated that PU-H71 has a good anti-malarial 
activity in  vitro and in mice [21]. Harmine, a beta car-
boline alkaloid, is able to selectively bind PfHsp90 to 
a greater extent than human Hsp90 (HsHsp90) [26]. 
Harmine has been reported as having a specific high-
affinity interaction with the ATP-binding domain of 
PfHsp90 with strong inhibition of P. falciparum in cell 
culture systems. In the P. berghei ANKA infection model 
in mice, harmine showed a significant reduction in 
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parasitaemia. However, it did not significantly prolong 
the survival of the infected mice [17, 26].
In this study, a library of harmine analogues were gen-
erated and their ability to bind PfHsp90, inhibit P. fal-
ciparum in culture, and kill parasites in the P. berghei 
infection mice model was tested. It was hypothesized 
that the harmine analogues have a strong anti-malarial 
effect both in vitro and in vivo in mice. It has been found 
that some of the harmine analogues effectively bind to 
PfHsp90, inhibit the growth of P. falciparum in vitro, sig-
nificantly reduce parasitaemia in infected BALB/c mice 
in a dose-dependent manner, and prolong the survival 
of infected mice. Interestingly, two daily injections with 
a combination of 100 mg/kg of 21A (one of the harmine 
analogues) and 10  mg/kg dihydro-artemisinin (DHA) 




Forty-two different analogues of harmine were generated 
using a microwave-assisted synthetic route, as described 
previously [27]. Based on the results of the PfHsp90 bind-
ing assay, two out of 42 compounds were selected and 
tested for in vitro and in vivo anti-malarial activity. The 
chemical structures of harmine 17A and 21A are shown 
in Fig. 1.
PfHsp90 competitive binding assay
Binding of the harmine-derived compounds with the 
ATP-binding domain of PfHsp90 was assessed using a 
bis-ANS (4, 4′-Dianilino-1, 1′-binaphthyl-5, 5′-disulfonic 
acid dipotassium salt) binding assay [28, 29]. The expres-
sion and purification of the PfHsp90 GHKL domain as 
well as the bis-ANS assay was performed as previously 
described [17]. Briefly, the P. falciparum Hsp90 GHKL 
domain DNA was cloned into pET28b plasmid vector 
and the His-tagged protein was expressed in Escherischia 
coli BL21 (DE3) CondonPlus cells. The recombinant pro-
tein was purified using Ni–NTA resin and the His-tag 
was cleaved using TEV protease. The competitive binding 
assay was performed by mixing bis-ANS with the puri-
fied recombinant protein that was pre-incubated at 37 °C 
in the presence or absence of the harmine analogues. The 
fluorescence emission was captured at 490 nm.
In vitro parasite culture and anti‑malarial activity assay
A 72-h in vitro growth inhibition assay was used to test 
the anti-malarial activity of the harmine analogues. 
Plasmodium falciparum line 3D7 (MRA-102), line W2 
(MRA-157), as well as artemisinin-resistant P. falciparum 
strains (MRA-1236 and MRA-1240) were obtained from 
MR4 (MR4, ATCC® Manassas, Virginia, USA). Plasmo-
dium falciparum was cultured in complete RPMI-1640 
medium with 1.5% haematocrit and incubated in a CO2-
enriched atmosphere. The parasite growth was synchro-
nized by treating with 5% sorbitol and cultured for 48 h. 
In  vitro susceptibility of the parasite to the candidate 
drugs was performed using histidine rich protein (HRP)-
II ELISA [30, 31]. First, the drug plates were prepared in 
ten-fold serial dilution with a total of ten drug concentra-
tions and one drug-free control in 96-well, flat-bottomed 
Costar® tissue culture plate (Corning, USA) in duplicate. 
Two-hundred µL of the parasite culture with a parasitae-
mia of 0.05% and a haematocrit of 1.5% was added into 
each well with a known drug concentration. The drug-
treated parasites were incubated at 37 °C in a candle jar 
for 72 h. Then, the plates were kept in a −20  °C freezer 
for at least 24  h before lysis of red blood cells was per-
formed by two freeze–thaw cycles.
HRP-II ELISA was performed following the proce-
dure in the Worldwide Antimalarial Resistance Network 
(WWARN) manual [32]. Briefly, a 96-well, high-binding 
ELISA plate (Costar®, Corning Inc, USA) was coated with 
1.0  µg/mL anti-HRP-II IgM capture antibody (Immu-
nology Consultants Laboratories, OR, USA) in PBS and 
incubated at 4 °C overnight. Next morning, the unbound 
antibody was removed by blotting on a paper towel and 
blocking was performed with 200  µL/well of 2% bovine 
serum albumin (BSA) at room temperature for 2 h. After 
removing the blocking buffer, the plate was washed twice 
with PBS containing 0.05% Tween® 20 (Sigma, MO, 
USA). One-hundred µL of the sample was then added 
to each well, incubated at room temperature for 1 h and 
washed twice as above. Then, 100  µL/well of a second-
ary anti-HRP-II antibody conjugated with horse radish 
peroxidase (Immunology Consultants Laboratories, OR, 
Fig. 1 The chemical structure of harmine analogues. Forty-two 
different analogues of harmine were generated using a microwave-
assisted synthetic route. Two compounds were selected based on 
their binding to the ATP-binding domain of pfHsp90. a Harmine, b 
17A and c 21A
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USA) diluted in 2% BSA/1% Tween® 20 in PBS was added 
and incubated for 1 h at room temperature. The plate was 
washed twice, and then 100  µL/well of TMB chromo-
gen (Invitrogen, CA, USA) was added and incubated for 
2–10 min at room temperature in the dark. The reaction 
was then stopped by adding 50  µL of 1  M sulfuric acid 
to each well. Finally, the absorbance at 450 nM was taken 
using a SpectraMax® 340 ELISA plate reader (Molecular 
Devices, USA).
In vivo anti‑malarial assay in mice
4- to 5-weeks old female BALB/c mice were purchased 
from Charles River Laboratories (QC, Canada). The mice 
were kept in a pathogen-free environment at the health 
science animal research facility of the University of Cal-
gary, Canada. A review of existing mouse malaria models 
has been described previously [33]. After acclimatizing 
for one week, four- to five-weeks old female BALB/c mice 
were randomly distributed to experimental and control 
groups. Each group consisted of five mice. Plasmodium 
berghei ANKA (kindly provided by Dr Ian Crandall, Uni-
versity of Toronto, ON, Canada) was thawed at 37  °C 
water bath and injected aseptically into the donor mice 
intraperitoneally. Blood was collected by cardiac punc-
ture when the parasitaemia reached 5–10%. Then, 106 
parasite-infected red blood cells (RBCs) were injected 
interaperitoneally into each mouse in the experimental 
and control groups. After confirmation of parasiatemia, 
each mouse in the experimental groups was given intra-
peritoneal injection of the experimental compound(s) 
dissolved in 10% dimethyl sulfoxide (DMSO). Positive 
and negative control mice were injected with chloroquine 
and DMSO, respectively. For the combination experi-
ment, 21A and DHA were prepared separately and mixed 
just before injection. The efficacy of the drugs was then 
assessed by determining the percentage of infected RBCs 
in Giemsa-stained blood collected by tail vein puncture 
daily. Survival of the drug-treated mice was compared 
with that of the controls. Mice that showed a net weight 
loss of more than 20% and with symptoms of severe 
malaria were euthanized.
Cytotoxicity assay
Cytotoxicity of the candidate drugs was tested on HepG2 
and HeLa cell lines using Cell Counting Kit-8 (Sigma). 
Immortalized human cell lines such as HepG2 and HeLa 
cells have been used in previous studies to assess the 
cytotoxicity of several compounds including anti-malar-
ial candidate drugs in  vitro [34–36]. All the cell culture 
reagents were bought from Life Technologies (Canada). 
HepG2 cells were cultured in DMEM (low glucose) plus 
10% FBS. HeLa cells were grown in DMEM (high glu-
cose) plus 10% FBS and 1 mM Pyruvate.
A modification of the procedure used by Ramirez-
Mares et  al. [37] was followed. Briefly, exponentially 
growing cells were trypsinized and suspended in fresh 
medium at a density of 5  ×  104 cells/ml. One-hundred 
µL of the cell suspension was then dispensed into each 
well of a 96-well, flat-bottomed Costar® tissue culture 
plate (Corning, USA) in triplicate and pre-incubated 
for 24 h in a humidified incubator at 37 °C and 5% CO2. 
Drug plates were prepared by serially diluting the drugs. 
Eight ten-fold dilutions of each drug were prepared start-
ing at 5  mM. In addition to the candidate drugs, chlo-
roquine, geldanamycin and DMSO were included as 
controls. Then, 10  µL/well of various concentrations of 
the drugs was added into the cells. Drug-free cells were 
also included as a control. The cells were then incu-
bated at 37  °C and 5% CO2 for 48  h. Then, 10 µL/well 
of CCK-8 reagent was added and incubated at 37 °C for 
an additional 4 h. Finally, the absorbance at 450 nm was 
measured using a SpectraMax® 340 ELISA plate reader 
(Molecular Devices, USA). Wells containing only media 
were also included as a control.
Statistical analysis
The statistical differences in per cent parasitaemia inhibi-
tion between drug-treated and vehicle control mice were 
analysed using t test. The log-rank (Mantel-Cox) test was 
done to analyse the statistical difference in the survival 
of drug-treated and control mice. A p value of less than 
0.05 was considered statistically significant. All statistical 
analyses were done using Graphpad Prism 6 software.
Results
Harmine analogues bind to PfHsp90
Of the 42 harmine analogues tested, two (17A and 21A) 
showed binding to the ATP-binding domain of PfHsp90. 
The average IC50 values for the binding of 17A and 21A 
with PfHsp90 were 12.2 ± 2.3 and 23.1 ± 8.8 µM, respec-
tively (Fig. 2). Unfortunately, 22 of the harmine analogues 
(the beta-carboline ‘B’ series of compounds) were not 
amenable to testing due to auto-fluorescence in the bis-
ANS assay and were subsequently excluded from further 
study.
Harmine analogues inhibit the growth of Plasmodium 
falciparum
The in  vitro anti-malarial efficacy of 17A and 21A was 
assessed against P. falciparum W2 using HRP-II ELISA in 
a whole cell assay. The average IC50 values were 4.2 ± 1.3 
and 5.7  ±  1.7  µM for 17A and 21A, respectively. The 
anti-malarial activity of 21A was also measured against 
artemisinin-resistant strains. It showed growth inhibi-
tion of MRA-1236 and MRA-1240 strains with average 
IC50 values of 9.2 ±  0.4 and 9.6 ±  2.0 µM, respectively. 
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Interestingly, 21A showed comparatively lower activity 
against chloroquine and artemisinin-sensitive P. falcipa-
rum 3D7 strain with average IC50 value of 13.5 ± 0.8 µM 
(Fig. 3).
Harmine analogues significantly reduce parasitaemia 
in infected mice and prolong their survival
The in vivo efficacy of the harmine analogue compounds 
was tested using P. berghei ANKA infection in BALB/c 
mice. For the fixed-dose experiment, the drug treat-
ment was started at day-4 post-infection with a starting 
average parasitaemia of about 3.5%. Three daily injec-
tions of infected mice with 100  mg/kg of each of 17A 
and 21A showed statistically significant reduction in 
parasitaemia compared to the vehicle control (p < 0.05). 
At day-7 post-infection (i.e., one day after the last dose 
of the drugs), 17A and 21A resulted in reduction of 
parasitaemia by 51.5 and 56.1%, respectively (Fig.  4a). 
The positive control mice that received a daily injec-
tion of 30  mg/kg chloroquine for three consecutive 
days cleared the infection to microscopically undetect-
able levels and remained so until the end of the experi-
ment. Figure 4b shows the Kaplan–Meier survival curve 
of the mice treated with the candidate drugs and con-
trols. Mice treated with 17A and 21A showed a median 
survival time of 11 and 14  days, respectively, while the 
vehicle control mice showed a median survival time of 
only 8.5 days. Log-rank (Mantel-Cox) test indicated that 
the survival of mice treated with 21A was significantly 
higher than vehicle control mice (p < 0.05). Of the two 
hamine-analogues tested for in vivo anti-malarial activ-
ity at a fixed dose, 21A was selected for a dose-ranging 
experiment. Four different doses of 21A were used for 
the dose-ranging experiment; 100, 75, 50 and 25  mg/
kg. Chloroquine and DMSO were used as a positive and 
vehicle controls, respectively. Five female BALB/c mice 
were used in each group. The degree of parasitaemia and 
survival rate in infected mice showed that 21A has anti-
malarial activity in a dose-dependent manner. One day 
after administration of the third dose, mice treated with 
100, 75 and 50 mg/kg demonstrated a significantly lower 
parasitaemia than the mice in the vehicle control group 
(p  <  0.05) (Fig.  5a). The per cent parasitaemia reduc-
tion in these groups was 48.1, 37.5 and 27.2%, respec-
tively. Like in the fixed-dose experiment, mice that were 
treated with chloroquine cleared the infection to micro-
scopically undetectable levels. Comparison of drug-
treated mice with the vehicle control ones indicated that 
at doses of 50  mg/kg and above, the survival of drug-
treated mice increased significantly than the controls 
(p < 0.05) (Fig. 5b).
21A has additive effect with dihydro‑artemisinin
In order to investigate the potential of 21A to be used 
as a partner drug with artemisinin in a combination 
therapy model, the anti-malarial efficacy of a combina-
tion of 21A and DHA was tested and compared—with 
the efficacy of the individual drugs alone. The data 
show that treatment with a combination of 100 mg/kg 
21A and 10 mg/kg DHA results in a more potent anti-
malarial activity than treatment with DHA alone. Fig-
ure  6a shows the per cent parasitaemia inhibition of 
treatment with a combination of 21A and DHA or with 
individual drugs alone. One day after administration of 
two doses of the combined drugs, all five mice (100%) 
cleared the infection with undetectable parasitaemia by 
microscopy. In contrast, only 40% (two out of five) of 
the mice treated with DHA alone cleared the infection 
at this time point. No mouse treated with 21A alone 
achieved undetectable parasitaemia. One day after the 
Fig. 2 Normalized dose–response curve for the competitive binding 
assay. Binding of (a) 17A and (b) 21A to the ATP binding domain of 
PfHsp90 was assessed using the bis-ANS competitive binding assay. 
Reduction in the fluorescence of bis-ANS was measured using a spec-
trophotometer. The average IC50 values were calculated from three 
experiments using Graphpad Prism 6. The mean fluorescence and 
standard error of the mean (SEM) of duplicate wells is shown. Each 
graph is a representative of three independent experiments
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last dose of treatment, 100 and 60% of the mice that 
received the combination and DHA alone had unde-
tectable parasitaemia, respectively (Fig.  6a). However, 
the mice that received the combination developed 
microscopically detectable parasitaemia at later time 
points. Likewise, the mice treated with a combination 
of 21A and DHA survived longer than those that were 
treated with either 21A or DHA alone. Two mice sur-
vived until the end of the experiment (day-16) and were 
sacrificed (Fig. 6b).
Fig. 3 Normalized dose–response curve for the in vitro susceptibility of Plasmodium falciparum to 17A and 21A. The in vitro anti-malarial effect of 
17A and 21A was measured using HRP-II ELISA of drug treated P. falciparum strains. a 17A against W2, b 21A against W2, c 21A against MRA-1236, d 
21A against MRA-1240, and e 21A against 3D7. IC50 values were calculated from the dose–response curve using Graphpad Prism 6. The experiment 
was performed in duplicate wells. The mean OD 450 nm and the standard error of the mean (SEM) of duplicate wells and is shown. Each graph is a 
representative of three independent experiments
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17A and 21A are not toxic to HepG2 and HeLa cells
To investigate the possibility of toxicity in human host, the 
cytotoxicity of the compounds was tested in vitro in HepG2 
and HeLa cells. The result showed that 17A and 21A are 
not toxic to either cell line. In HepG2 cells, the IC50 values 
of 17A and 21A were 0.16 ± 0.01 and 0.140 ± 0.001 mM, 
respectively. On the other hand, in HeLa cells, 17A and 
21A had IC50 values of 1.1 ± 0.3, 0.48 ± 0.14 mM, respec-
tively (Fig.  7). Since it has proven hepatotoxicity, geldan-
amycin was also included as a control. As expected, it 
showed high degree of toxicity in HepG2 cells with IC50 in 
micromolar range (0.34 ± 0.13 µM).
Discussion
Heat shock proteins are crucial molecular chaperones 
that are involved in various central metabolic activities of 
both prokaryotic and eukaryotic cells. Because Hsps are 
necessary for normal metabolic activities of a cell and to 
protect cells from stress conditions, they are conserved in 
all life forms. Although they are constitutively expressed, 
the level of expression of Hsps increases when challenged 
by stressors such as heat or pH changes. Hsp90’s crucial 
role as an essential chaperone, association with resist-
ance, and high degree of conservation make it an attrac-
tive adjunctive drug target [18, 19, 38, 39].
As a parasite with a life cycle involving poikilother-
mic insects and homoeothermic humans, P. falciparum 
has to adapt to the drastic change in temperature dur-
ing transmission from the insect vector to human host. 
Plasmodium falciparum Hsp90 protein is the most abun-
dant cytosolic protein and plays an indispensable role 
in resisting the effect of temperature change that occurs 




























Fig. 4 Parasitaemia inhibition and survival of mice treated with a 
fixed dose of harmine-analogues. Five BALB/c mice per group were 
infected with P. berghei ANKA. The mice were treated with three daily 
doses of 100 mg/kg of 17A or 21A starting at day-4 post infection. 
The positive and negative control mice were given three daily doses 
of 100 mg/kg chloroquine and 10% DMSO, respectively. a Per cent 
parasitaemia. The graph is the mean parasitaemia and standard error 
of the mean (SEM) of five mice in a group, and b Kaplan–Meier sur-
vival plot of mice treated with the harmine analogues and controls. 
Asterisk indicates a statistically significant difference between the 























Fig. 5 Parasitaemia inhibition and survival of mice treated with 
different doses of 21A. Five BALB/c mice per group were infected 
with P. berghei ANKA. The mice were treated with three daily doses of 
100, 75, 50 or 25 mg/kg of 21A starting at day-3 post infection. The 
positive and negative control mice were given three daily doses of 
30 mg/kg chloroquine and 10% DMSO, respectively. a Per cent parasi-
taemia. The graph is the mean parasitaemia and standard error of the 
mean (SEM) of five mice in a group, and b Kaplan–Meier survival plot 
of mice treated with different doses of 21A and controls. Asterisk indi-
cates a statistically significant difference between the drug treated 
mice and the vehicle control group (DMSO)
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The ATPase activity of Hsp90 is a necessary precur-
sor to its function and interaction with client proteins. 
Therefore, targeting the Hsp90 ATP-binding using a 
small molecule is expected to inhibit its chaperoning 
activity and render the client proteins to degradation via 
the cytosolic proteasome, which consequently inhibit 
major metabolic activities of the cell [40]. Several stud-
ies have tested the use of small molecules that bind to 
and competitively inhibit the ATPase activity of Hsp90 
as candidate drugs for different infectious diseases and 
cancer [23, 41, 42]. Although the Hsp90 in humans and 
the malaria parasite have a high degree of homology, 
there are subtle and potentially significant structural dif-
ferences that can be exploited when designing selective 
small-molecule inhibitors [16]. Moreover, cells from dif-
ferent organisms show variable degree of dependency on 
chaperone-supported metabolic activities. As a result, it 
is hypothesized that it is possible to inhibit the activity of 
Hsp of a pathogen without significant deleterious effects 
on the Hsps of the host [5, 17]. It has been shown previ-
ously that natural compounds such as harmine and the 
ATP mimetic PU-H71 exert anti-Plasmodium activity 
by targeting PfHsp90 [21, 26]. In this study, 42 different 
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Fig. 6 Parasitaemia inhibition and survival of mice treated with a combination of 21A and dihydro-artemisinin. Five BALB/c mice per group were 
infected with P. berghei ANKA. The mice were treated with three daily doses of 100 mg/kg 21A, 10 mg/kg DHA, a combination of 100 mg/kg 21A 
and 10 mg/kg DHA starting at day-3 post infection. The negative control mice were given three doses of 10% DMSO. a Per cent parasitaemia. The 
graph is the mean parasitaemia and standard error of the mean (SEM) of five mice in a group, and b Kaplan–Meier survival plot of mice treated with 
21A, DHA, and a combination of 21A and DHA
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and in vivo anti-malarial activities of two of the harmine 
analogues was tested as single agents and in combination 
with artemisinin. Unfortunately, 22 harmine analogues 
displayed auto-fluorescence in bis-ANS assay and were 
consequently excluded from the study.
Two out of the remaining 20 compounds (17A and 
21A) effectively bind to the ATP-binding domain of 
PfHsp90 with IC50 value in the low micromolar range. 
The IC50 values of 17A and 21A was comparable to that 
of radicicol, a compound that has been shown to tightly 
bind Hsp90 [43].
In vitro susceptibility of 21A showed that the com-
pound has anti-malarial activity against both chloro-
quine- and artemisinin-resistant P. falciparum strains 
with micromolar IC50 value. Generally, the chloroquine- 
or artemisinin-resistant strains seem more susceptible 
to 21A than the chloroquine-sensitive 3D7 strain. Simi-
lar effect was seen in the previous study with harmine. 
That is, chloroquine-resistant W2 strain was almost 
twice more susceptible to harmine than chloroquine-
sensitive 3D7 strain [17]. It remains to be seen if inhibi-
tion of PfHsp90 in chloroquine-resistant strains affects 
other metabolic activities of the parasite in addition to 
reversing the resistance trait. The effect of inhibition of 
PfHsp90 activity on proteins associated with chloro-
quine- or artemisinin-resistance needs further study.
At a fixed dose of 100  mg/kg administered daily for 
three consecutive days, both 17A and 21A showed a sig-
nificant parasitaemia reduction. Unlike 17A, treatment 
with 21A significantly prolonged the survival time of 
treated mice. This property was not seen with the par-
ent molecule harmine [26]. Therefore, 21A was selected 
for the dose-ranging and combination experiments. 
21A showed a dose-dependent activity with the high-
est parasitaemia reduction at a dose of 100  mg/kg fol-
lowed by 75 and 50 mg/kg. One day after the last dose of 
Fig. 7 Normalized dose–response curve for in vitro cytotoxicity of 17A and 21A. Human cell lines were cultured in the presence of 17A and 21A. 
Cytotoxicity of the compounds was evaluated using the CCK-8 kit. Per cent cell death was measured by measuring absorbance at OD 450 nm. 
a HepG2 cells treated with 17A, b HepG2 cells treated with 21A, c HeLa cells treated with 17A, and d HeLa cells treated with 21A. The mean OD 
450 nm and the standard error of the mean (SEM) of triplicate wells and is shown. Each graph is representative of three independent experiments
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treatment, the group treated with 25 mg/kg did not show 
significant difference from the vehicle control. Interest-
ingly, 21A showed an additive effect with DHA in vivo in 
mice. Treatment with a combination of 100  mg/kg 21A 
and 10 mg/kg DHA resulted in a dramatic reduction of 
parasitaemia to undetectable levels by microscopy on 
Giemsa-stained peripheral blood in just two doses. This 
stands in stark contrast with the result from mice that 
were treated with DHA alone where only two out of five 
mice cleared the infection. As such, 21A has promising 
potential as a partner drug with artemisinin either in 
combination or co-formulation. This is in line with pre-
vious studies that showed the possibility of using Hsp90 
inhibitors as adjunctive drugs with the current anti-
malarial drugs [39]. Of note, it is not possible to deter-
mine if the combined effect in mice was due to synergy 
or an alternative effect. Because the parasitaemia in the 
combination treatment groups was reduced to undetect-
able levels by microscopy, it was not possible to calculate 
whether 21A has synergistic effect with DHA in  vivo. 
FACS analysis of DNA-stained RBCs could have been 
an alternative approach to determine the parasite load 
in such conditions. However, FACS analysis was not per-
formed due to lack of the required laboratory facility. 
On the other hand, pharmacokinetic analysis of 21A and 
DHA in mice was not performed in this study. Pharma-
cokinetic and drug–drug interaction study between 21A 
and DHA is warranted to better understand the synergy.
In this study, differences were seen in the parasitaemia 
of mice that were treated with the same amount of 21A 
in different experiments. This could be probably due to 
differences in experimental conditions. One such factor 
is the difference in the initial parasitaemia before drug 
administration.
In order to be considered as an effective candidate 
drug, a compound should not be toxic to the human host. 
The first step in evaluating toxicity is to investigate the 
cytotoxicity in cell lines in vitro. In this regard, the cyto-
toxicity of 17A and 21A was tested in HepG2 and HeLa 
cells in vitro. Comparing the IC50 value for the cytotoxic-
ity with that of in  vitro anti-malarial activity, in HepG2 
cells, 17A and 21A had a favourable cytotoxicity selec-
tivity index (SI) of 38 and 25, respectively. In HeLa cells, 
17A and 21A had an SI of 259 and 84, respectively. Future 
studies require the pursuit of a second generation library 
based on the current data which probably will yield com-
pounds with increased potency against malaria in all 
stages of the life cycle.
Conclusion
The emergence of P. falciparum strains that are resistant to 
artemisinin or to the partner drugs in ACT poses a seri-
ous challenge to the current malaria elimination agenda. 
This calls for the development of new ‘smart’ drugs that 
could be used as partner drugs with artemisinin. It has 
been previously shown that P. falciparum Hsp90 is highly 
conserved and performs a fundamental chaperone role 
in the cell. Harmine analogues that inhibit PfHsp90 have 
been developed and their anti-malarial activity tested 
in  vitro and in  vivo in mice. Two harmine analogues, 
17A and 21A, showed in  vitro anti-malarial activity with 
micromolar range IC50 values. The analogues also showed 
in vivo anti-malarial activity with significant parasitaemia 
reduction in infected BALB/c mice and increased survival. 
More importantly, 21A showed additive effects when used 
in combination with DHA, indicating that 21A could be 
potentially used as a partner drug candidate. Future study 
on the pharmacokinetics of 21A and also drug–drug inter-
action with DHA would be of great importance.
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